Sugi Predict

Sugi Predict / Compounds / SCHEMBL473734

SCHEMBL473734

SCHEMBL473734

CCOC(O)n1c(N)nc2[nH]cnc2c1=O

nearest known ligand 0.32

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 4/20 0.32
▸ PDE4A P27815 3/20 0.32
▸ PDE4B Q07343 3/20 0.32
▸ PDE4C Q08493 3/20 0.32
▸ PDE4D Q08499 3/20 0.32
▸ ADORA2B P29275 3/20 0.32
▸ LMNA P02545 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ CDK1 P06493 1/20 0.31
▸ CCNB1 P14635 1/20 0.31
▸ CCNA2 P20248 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ CCNA1 P78396 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6751928 0.81 ADORA2B (0.35) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL5503610 0.80 CDK1 (0.42) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL15743132 0.79 ADORA2A (0.33) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL5021599 0.78 ADORA2B (0.43) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL9806961 0.77 ADORA2B (0.36) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL2249841 0.77 HPRT1 (0.37) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL6847248 0.77 PDE4A (0.33) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL385152 0.76 HPRT1 (0.38) —
SCHEMBL441795 0.76 ADORA2B (0.35) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL2113436 0.75 ADORA2A (0.33) ADORA2APDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011056630-A2 SMALL MOLECULE INHIBITORS OF HEPATITIS C VIRUS TRUSTEES OF BOSTON UNIVERSITY (US) 2011-05-12 — — WO claimed
EP-4735462-A1 COMPOUNDS AND USES THEREFOR GLYCOSYNNOVATIONS PTY LTD (AU) 2026-05-06 — — EP disclosed
US-20250195501-A1 CELL ENTRY-MODULATING AGENTS AND USES THEREFOR GRIFFITH UNIVERSITY (AU) 2025-06-19 — — US disclosed
US-20250144066-A1 Prevention and Treatment of Parasitic Infections BARANOWITZ STEVEN (US) 2025-05-08 — — US disclosed
WO-2025064458-A1 PREVENTION AND TREATMENT OF VIRAL INFECTIONS BARANOWITZ STEVEN (US) 2025-03-27 — — WO disclosed
US-12226392-B2 Prevention and treatment of viral infections BARANOWITZ STEVEN (US) 2025-02-18 — — US disclosed
WO-2025000059-A1 COMPOUNDS AND USES THEREFOR Glycosynnovations Pty Ltd (AU) 2025-01-02 — — WO disclosed
US-20240299337-A1 Prevention and Treatment of Viral Infections BARANOWITZ STEVEN (US) 2024-09-12 — — US disclosed
US-12011429-B2 Prevention and treatment of viral infections BARANOWITZ STEVEN (US) 2024-06-18 — — US disclosed
US-20240066004-A1 Prevention and Treatment of Viral Infections BARANOWITZ STEVEN (US) 2024-02-29 — — US disclosed
US-20050158449-A1 Method and apparatus for coating of substrates Surmodics Coatings, LLC 2005-07-21 — — US disclosed
US-20050136483-A1 Nanodevices employing combinatorial artificial receptors RECEPTORS LLC (US) 2005-06-23 — — US disclosed
WO-2005053835-A2 ARTIFICIAL RECEPTORS INCLUDING GRADIENTS RECEPTORS LLC (US) 2005-06-16 — — WO disclosed
WO-2005024382-A9 NANODEVICES EMPLOYING COMBINATORIAL ARTIFICIAL RECEPTORS RECEPTORS LLC (US) 2005-06-09 — — WO disclosed
US-20050106630-A1 Building blocks for artificial receptors RECEPTORS LLC (US) 2005-05-19 — — US disclosed
WO-2005024382-A2 NANODEVICES EMPLOYING COMBINATORIAL ARTIFICIAL RECEPTORS RECEPTORS LLC (US) 2005-03-17 — — WO disclosed
WO-2005024433-A2 BUILDING BLOCKS FOR ARTIFICIAL RECEPTORS RECEPTORS LLC (US) 2005-03-17 — — WO disclosed
EP-1309360-A2 MEDICAMENT INCORPORATION MATRIX SurModics, Inc. (US) 2003-05-14 — — EP disclosed
US-20020041899-A1 Medicament incorporation matrix Surmodics Coatings, LLC 2002-04-11 — — US disclosed
WO-2002013871-A2 MEDICAMENT INCORPORATION MATRIX SURMODICS, INC. (US) 2002-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195501-A1 CELL ENTRY-MODULATING AGENTS AND USES THEREFOR ACE2, ACE, TMPRSS2 ADORA2A 2024/4885PDE4A 2501/4885PDE4B 1566/4885
US-12011429-B2 Prevention and treatment of viral infections MAVS, HAVCR2, NEU4 ADORA2A 286/4885PDE4A 1021/4885PDE4B 1151/4885
US-20250144066-A1 Prevention and Treatment of Parasitic Infections EPX, CTSA, SERPINB1 ADORA2A 2923/4885PDE4A 1342/4885PDE4B 1476/4885
US-20020041899-A1 Medicament incorporation matrix COL14A1, MATR3, ECPAS ADORA2A 2502/4885PDE4A 4390/4885PDE4B 4716/4885
US-12226392-B2 Prevention and treatment of viral infections MAVS, HAVCR2, MTREX ADORA2A 1354/4885PDE4A 1909/4885PDE4B 2082/4885
US-20240299337-A1 Prevention and Treatment of Viral Infections MAVS, HAVCR2, NEU4 ADORA2A 286/4885PDE4A 1021/4885PDE4B 1151/4885
US-20240066004-A1 Prevention and Treatment of Viral Infections MAVS, HAVCR2, NEU4 ADORA2A 286/4885PDE4A 1021/4885PDE4B 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.